Topic: infectious respiratory diseases
The writedown comes months after J&J took a $630 million hit tied to the suspension of clinical development of AL-8176.
Novavax’s RSV shot missed another phase 3 trial, causing the company’s stock price to lose about two-thirds of its remaining value premarket.
Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
U.K. biotech hVIVO is on course to start a phase 3 program for a flu vaccine that doesn’t need to have its composition tweaked every year.
Four years ago, J&J splashed out $1.75 billion to take control of antiviral firm Alios, but the lead drug from that deal now seems to be in trouble.
Insights into how bacteria hibernate and use metals to evade destruction by antibiotics could be useful in drug development.
Developing new biologic drugs for tough-to-treat viral diseases.
Armed with positive phase 2b data, resTORbio is planning pivotal trials next year for a drug to prevent respiratory tract infections in the elderly.
Qiagen will gain control of a pipeline of assay panels designed to diagnose infections affecting the respiratory and gastrointestinal systems.
Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.